Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMT310 in Acne Vulgaris
NCT03536637Phase 2Completed
- Sponsor
- Dermata Therapeutics
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DMT310 in acne vulgaris, sponsored by Dermata Therapeutics. Started May 2018; status: completed.
02
Drugs
DMT310
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03536637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536637.